ADARx Pharmaceuticals
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5871 Oberlin Dr Ste 200, San Diego, Cali...Phone Number
(877) 232-7974Website
www.adarx.comRevenue
<$5 MillionStock Symbol
ADRXIndustry
About ADARx Pharmaceuticals
ADARx Pharmaceuticals is a San Diego, California-based late-stage clinical biotechnology company founded in 2019 that develops next-generation RNA medicines using proprietary RNA-targeted therapies. The company is advancing a pipeline of selective and durable candidates targeting complement-mediated, genetic, cardiovascular, thrombotic, central nervous system, and metabolic diseases. ADARx was founded by Zhen Li, who serves as President and CEO, and has partnered with AbbVie to expand its siRNA technology into neuroscience, immunology, and oncology.Explore more
ADARx Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to ADARx Pharmaceuticals
Compare insights from companies similar to ADARx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ADARx Pharmaceuticals Tech Stack
A closer look at the technologies used by ADARx Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ADARx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
ADARx Pharmaceuticals is a San Diego, California-based late-stage clinical biotechnology company founded in 2019 that develops next-generation RNA medicines using proprietary RNA-targeted therapies. The company is advancing a pipeline of selective and durable candidates targeting complement-mediated, genetic, cardiovascular, thrombotic, central ner... Read More
